Is Elective Caesarian Section Really Necessary for Prevention of Mother to Child Transmission of HIV in the HAART Era?

There is ongoing debate about the necessity to use caesarian section for the prevention of mother to child transmission (MTCT) of HIV in settings where HAART is used and breastfeeding is withheld.

The objective of the current retrospective analysis, conducted at the B.J Waida Hospital for Children in Parel, Mumbai, India, was to determine whether vaginal delivery along with antiretroviral therapy and avoidance of breastfeeding is safe in preventing MTCT of HIV.

Two hundred twenty-two (222) HIV positive pregnant women were treated with zidovudine (AZT; Retrovir) from 14 weeks of gestation onwards. One hundred seventy-four (174) women underwent an elective caesarian section whereas 48 women delivered spontaneously vaginally.

All infants were treated with zidovudine for 6 weeks and breastfeeding was withheld. The HIV status of the infants was determined at 18 months by ELISA test.

Results

Of the 174 infants delivered through LSCS delivery, two were HIV-infected whereas 172 (98.9%) were HIV uninfected.

Of the 48 infants delivered vaginally, 47 (97.9%) were HIV negative and one child was HIV-infected.

The author of the present study concludes, “Thus, elective caesarean section was not statistically better as compared to vaginal delivery ( p = 0.8696) suggesting that vaginal delivery was as effective as caesarean section for prevention of MTCT of HIV when added with antiretroviral therapy and no breastfeeding.”

“Vaginal delivery along with antiretroviral therapy in mother and baby and avoidance of breastfeeding is equivalent to that of an elective LSCS delivery for prevention of mother-to-child transmission of HIV. Surgical intervention may thus not be required in these women.”

Department of Perinatal and Pediatric HIV Clinic, B. J. Wadia Hospital for Children, Parel, Mumbai, India.

04/07/06

Reference
I Shah. Is Elective Caesarian Section Really Essential for Prevention of Mother to Child Transmission of HIV in the Era of Antiretroviral Therapy and Abstinence of Breast Feeding? Journal of Tropical Pediatrics March 29, 2006 [Epub ahead of print].

 

 

 


 


FDA-Approved
Treatments

Protease Inhibitors

Agenerase
(amprenavir)


Aptivus
(Tipranavir)


Crixivan
(indinavir)


Fortovase
(saquinavir soft gel capsules)


Invirase
(saquinavir hard gel capsules)


Lexiva

(Fosamprenavir)


Norvir
(ritonavir)


Reyataz
(atazanavir)


Viracept

(nelfinavir)


Nucleoside / Nucleotide Reverse Transcriptase Inhibitors


Combivir
(AZT plus 3TC)


Epivir
(lamivudine; 3TC)


Emtriva
(emtricitabine; FTC)


 Epzicom
(abacavir + lamivudine)


Hivid
(zalcitabine; ddC)


Retrovir
(zidovudine; AZT)


Trizivir
(abacavir plus zidovudine plus lamivudine)


Videx
(didanosine; ddI)


Viread
(tenofovir)



Zerit
(stavudine; d4T)



Ziagen
(abacavir)


non Nucleoside Reverse Transcriptase Inhibitors

Rescriptor
(delavirdine)



Sustiva
(efavirenz)


Viramune
(nevirapine)

Entry Inhibitors

Fuzeon
(enfuvirtide; T-20)